Drug Trial Radar · NCT05041907
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,800
Planned (sponsor's estimate)
Start
Sep 30, 2021
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity. In this randomized open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment): A: Small molecule drugs; B: Monoclonal antibodies; C: Dose finding for the constituent parts of nirmatrelvir/ritonavir PLATCOV study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.
Conditions
- COVID-19
Interventions
Nirmatrelvir/ritonavir (e.g. PAXLOVID™)Drug
Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7
NitazoxanideDrug
Nitazoxanide 1.5g BD 7/7
Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)Drug
Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7
HydroxychloroquineDrug
Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7
No treatmentOther
No treatment (except antipyretics- paracetamol)
Monoclonal antibodiesDrug
Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
FluoxetineDrug
Fluoxetine 40mg OD for 7/7
MolnupiravirDrug
Molnupiravir 800mg BD for 5/7
SotrovimabDrug
Sotrovimab 500mg given once on D0
EnsitrelvirDrug
Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7
Monoclonal antibodiesDrug
Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
FavipiravirDrug
Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7
IvermectinDrug
Ivermectin 600micrograms/kg/day for 7/7.
RemdesivirDrug
Remdesivir 200mg D0 and 100mg for a further 4/7.
Atilotrelvir/ritonavirDrug
Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7
MetforminDrug
Metformin 500mg TDS 5/7
Nirmatrelvir/ritonavirDrug
Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7
Nirmatrelvir/ritonavirDrug
Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7
NirmatrelvirDrug
Nirmatrelvir 300mg BD for 5/7
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of viral clearance for interventions relative to the no study arm (This is a superiority comparison)Time frame: Days 0-5
- Rate of viral clearance for interventions relative to the positive control arm (This is a non-inferiority or superiority comparison).Time frame: Days 0-5
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
Universidade Federal de Minas Gerais
Minas Gerais, Brazil · Recruiting
Laos-Oxford-Mahosot Wellcome Trust Research Unit
Vientiane, Laos · Recruiting
Sukraraj Tropical & Infectious Disease Hospital
Kathmandu, Nepal · Recruiting
The Aga Khan University Hospital
Karachi, Pakistan · Terminated
Vajira hospital
Bangkok, Thailand · Terminated
Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand · Recruiting
Bangplee Hospital
Mueang Samut Prakan, Thailand · Terminated
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.